The first major study to include such patients was BCIRG-006—a phase 3 clinical trial examining the clinical outcomes of those with early HER2 + BC who received an adjuvant chemotherapy regimen of either AC-T (doxorubicin and cyclophosphamide followed by docetaxel), AC-TH (AC-T in combination with 1 year of trastuzumab), or anthracycline-free TCH (docetaxel and carboplatin in combination with 1 year of trastuzumab)6,7. Here, ERBB2 is linked to breast cancer.